Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Total Current Liabilities (2023 - 2025)

Mangoceuticals' Total Current Liabilities history spans 3 years, with the latest figure at $804275.0 for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 42.2% year-over-year to $804275.0; the TTM value through Sep 2025 reached $804275.0, down 42.2%, while the annual FY2024 figure was $1.4 million, 575.33% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $804275.0 at Mangoceuticals, down from $1.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.6 million in Q2 2025 and bottomed at $159176.0 in Q3 2023.
  • The 3-year median for Total Current Liabilities is $1.2 million (2024), against an average of $915027.8.
  • The largest annual shift saw Total Current Liabilities soared 774.12% in 2024 before it tumbled 42.2% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $211078.0 in 2023, then skyrocketed by 575.33% to $1.4 million in 2024, then tumbled by 43.58% to $804275.0 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Total Current Liabilities are $804275.0 (Q3 2025), $1.6 million (Q2 2025), and $1.5 million (Q1 2025).